Nektar Therapeutics (NKTR) Capital Expenditures Growth (3y) (2013 - 2026)
Nektar Therapeutics (NKTR) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Nektar Therapeutics | 1.76 Bn | 1.19 Bn | 3.16 Mn | -65.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.36% |
| Dec 31, 2025 | -67.24% |
| Sep 30, 2025 | -14.28% |
| Jun 30, 2025 | -63.80% |
| Mar 31, 2025 | -92.19% |
| Dec 31, 2024 | -57.30% |
| Sep 30, 2024 | -39.01% |
| Jun 30, 2024 | -61.58% |
| Mar 31, 2024 | -62.07% |
| Dec 31, 2023 | -48.69% |
| Sep 30, 2023 | -74.15% |
| Jun 30, 2023 | -60.82% |
| Mar 31, 2023 | -21.64% |
| Dec 31, 2022 | -48.14% |
| Sep 30, 2022 | -67.60% |
| Jun 30, 2022 | -59.39% |
| Mar 31, 2022 | -9.38% |
| Dec 31, 2021 | -12.12% |
| Sep 30, 2021 | 17.24% |
| Jun 30, 2021 | 6.13% |